Fmr LLC Increases Holdings in Genmab A/S (NASDAQ:GMAB)

FMR LLC boosted its holdings in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 13.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 278,194 shares of the company's stock after purchasing an additional 33,076 shares during the quarter. FMR LLC's holdings in Genmab A/S were worth $6,782,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of GMAB. Oppenheimer Asset Management Inc. increased its stake in shares of Genmab A/S by 26.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company's stock worth $5,480,000 after purchasing an additional 45,376 shares in the last quarter. Choreo LLC acquired a new position in Genmab A/S in the 2nd quarter valued at $776,000. Renaissance Technologies LLC boosted its stake in Genmab A/S by 7.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company's stock worth $36,752,000 after purchasing an additional 103,859 shares during the last quarter. Natixis Advisors LLC boosted its stake in Genmab A/S by 29.8% during the 3rd quarter. Natixis Advisors LLC now owns 206,563 shares of the company's stock worth $5,036,000 after purchasing an additional 47,437 shares during the last quarter. Finally, US Bancorp DE raised its position in shares of Genmab A/S by 16.0% in the third quarter. US Bancorp DE now owns 171,669 shares of the company's stock valued at $4,185,000 after buying an additional 23,723 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

GMAB has been the topic of a number of research reports. Redburn Atlantic started coverage on shares of Genmab A/S in a research note on Tuesday, October 8th. They issued a "buy" rating on the stock. Morgan Stanley reissued an "equal weight" rating and set a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. Truist Financial cut their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a "buy" rating for the company in a research report on Monday, September 9th. BMO Capital Markets reiterated an "outperform" rating and issued a $48.00 target price (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, JPMorgan Chase & Co. reissued a "neutral" rating on shares of Genmab A/S in a research note on Tuesday, August 20th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $45.20.

Genmab A/S Price Performance

Shares of NASDAQ GMAB traded down $0.48 during mid-day trading on Friday, hitting $20.17. The company had a trading volume of 859,850 shares, compared to its average volume of 735,194. The company has a market capitalization of $13.35 billion, a PE ratio of 20.05, a price-to-earnings-growth ratio of 0.67 and a beta of 0.96. The business's 50-day simple moving average is $22.22 and its 200 day simple moving average is $25.14. Genmab A/S has a 1-year low of $20.12 and a 1-year high of $32.88.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The company had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same period in the prior year, the business earned $0.47 EPS. On average, analysts expect that Genmab A/S will post 1.28 EPS for the current year.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.